A Murias

420 total citations
17 papers, 123 citations indexed

About

A Murias is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, A Murias has authored 17 papers receiving a total of 123 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in A Murias's work include Cancer Treatment and Pharmacology (8 papers), Breast Cancer Treatment Studies (5 papers) and HER2/EGFR in Cancer Research (5 papers). A Murias is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Breast Cancer Treatment Studies (5 papers) and HER2/EGFR in Cancer Research (5 papers). A Murias collaborates with scholars based in Spain, Austria and Australia. A Murias's co-authors include Manuel Constenla, F. Carabantes, Johan Ahlgren, A. Ruíz, G. Pérez-Manga, Kenneth Villman, Manuel González Barón, Jorge Castellanos, Martin Söderberg and Eduardo García‐Rico and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Cancer Research.

In The Last Decade

A Murias

16 papers receiving 119 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A Murias Spain 6 86 52 32 19 15 17 123
K. P. Theall United States 4 95 1.1× 27 0.5× 70 2.2× 23 1.2× 11 0.7× 9 140
Lokesh Viswanath India 7 59 0.7× 48 0.9× 8 0.3× 28 1.5× 31 2.1× 14 115
María José Echarri Spain 5 101 1.2× 71 1.4× 19 0.6× 15 0.8× 19 1.3× 7 146
Ina Valeria Zurlo Italy 6 105 1.2× 89 1.7× 40 1.3× 42 2.2× 30 2.0× 24 191
Catherine Becht France 6 84 1.0× 32 0.6× 27 0.8× 11 0.6× 14 0.9× 9 123
Nicholas Venturini United States 5 87 1.0× 53 1.0× 21 0.7× 13 0.7× 2 0.1× 9 164
Brian Hunis United States 6 57 0.7× 41 0.8× 24 0.8× 33 1.7× 6 0.4× 28 111
Yakup Ergün Türkiye 7 122 1.4× 58 1.1× 62 1.9× 24 1.3× 3 0.2× 44 181
Alicia‐Marie Conway United Kingdom 6 85 1.0× 19 0.4× 40 1.3× 30 1.6× 15 1.0× 13 129

Countries citing papers authored by A Murias

Since Specialization
Citations

This map shows the geographic impact of A Murias's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A Murias with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A Murias more than expected).

Fields of papers citing papers by A Murias

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A Murias. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A Murias. The network helps show where A Murias may publish in the future.

Co-authorship network of co-authors of A Murias

This figure shows the co-authorship network connecting the top 25 collaborators of A Murias. A scholar is included among the top collaborators of A Murias based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A Murias. A Murias is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Gnant, Michael, Hiroji Iwata, Robert Šeparović, et al.. (2018). Duration of extended adjuvant therapy with neratinib in early-stage HER2+ breast cancer after trastuzumab-based therapy: Exploratory analyses from the phase III ExteNET trial.. Journal of Clinical Oncology. 36(15_suppl). 524–524. 1 indexed citations
2.
Salvador, J., Luís Manso, Juan de la Haba-Rodríguez, et al.. (2014). Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Clinical & Translational Oncology. 17(2). 160–166. 10 indexed citations
3.
Grávalos, Cristina, Carlos García Girón, Rocio García‐Carbonero, et al.. (2012). A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer. Clinical & Translational Oncology. 14(8). 606–612. 20 indexed citations
4.
Salvador, J., Eva Ciruelos, António Galán de Mera, et al.. (2012). AVALUZ study: First line with bevacizumab in combination with paclitaxel (P) and gemcitabine (G) in patients with HER2-negative or recurrent mBC: OS analysis.. Journal of Clinical Oncology. 30(15_suppl). e11535–e11535. 1 indexed citations
5.
Haba-Rodríguez, Juan de la, Javier Salvador Bofill, Eva Ciruelos, et al.. (2012). Study of the usefulness of angiotensin type 1 receptor (AGTR1) as a possible response predictor in patients with metastatic breast cancer (mBC) subjected to chemotherapy and treatment with bevacizumab (AVALUZ Study).. Journal of Clinical Oncology. 30(15_suppl). 10608–10608.
6.
7.
Salvador, J., Eva Ciruelos, António Galán de Mera, et al.. (2011). P1-14-03: AVALUZ Study: First Line with Bevacizumab in Combination with Paclitaxel (P) and Gemcitabine (G) in Patients with HER-2 Negative Recurrent or Metastatic BC: PFS Analysis.. Cancer Research. 71(24_Supplement). P1–14. 1 indexed citations
8.
Ruíz‐Borrego, Manuel, J. Salvador, F. Carabantes, et al.. (2009). Different Treatment Benefit for Luminal A and Luminal B Advanced Breast Cancinomas Receiving Aromatase Inhibitors.. Cancer Research. 69(24_Supplement). 5141–5141. 2 indexed citations
9.
10.
Aparicio, Jorge, José L. García-Puche, M. Lomas, et al.. (2006). Prognostic factors for relapse in stage I seminoma managed by surveillance or adjuvant carboplatin: A multivariate analysis on 588 cases. Journal of Clinical Oncology. 24(18_suppl). 4552–4552. 3 indexed citations
11.
Font, Albert, A Murias, Cristina Martín, et al.. (2005). Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study. Annals of Oncology. 16(3). 419–424. 13 indexed citations
12.
Cabrera‐Andrade, Alejandro, et al.. (2005). The androgen receptor gene polymorphisms in human breast cancer: short CAG repeats are associated with lymph node involvement. Acceda (Universidad de Las Palmas de Gran Canaria). 1 indexed citations
13.
Pérez-Manga, G., Manuel Constenla, A. Ruíz, et al.. (2004). Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer. British Journal of Cancer. 90(9). 1740–1746. 42 indexed citations
14.
Bohn, Uriel, Cristina Bilbao, A Murias, et al.. (2002). Prognostic value of the quantitative measurement of the oncoprotein p185Her‐2/neu in a group of patients with breast cancer and positive node involvement. International Journal of Cancer. 101(6). 539–544. 8 indexed citations
15.
Millà, A., P. Escudero, Antonieta Salud, et al.. (2001). An ongoing phase II study of tomudex (raltitrexed) plus irinotecan in advanced colorectal cancer. European Journal of Cancer. 37. S301–S301. 3 indexed citations
16.
Graeven, Ullrich, Karsten Ridwelski, M.P. Manns, et al.. (2001). CPT-11 combined or alternated with 5 fluoruracil/folinic acid (5-FU/FA) vs mayo clinic regimen in first line therapy of advanced colorectal cancer (ACRC). Gastroenterology. 120(5). A611–A611. 1 indexed citations
17.
Tejedor, M. Cristina, et al.. (1992). Induction chemotherapy with carboplatin and ftorafur in advanced head and neck cancer. A randomized study.. PubMed. 15(5). 417–21. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by K. P. Theall Breakdown of academic impact, for papers by Lokesh Viswanath Breakdown of academic impact, for papers by María José Echarri Breakdown of academic impact, for papers by Ina Valeria Zurlo Breakdown of academic impact, for papers by Catherine Becht Breakdown of academic impact, for papers by Nicholas Venturini Breakdown of academic impact, for papers by Brian Hunis Breakdown of academic impact, for papers by Yakup Ergün Breakdown of academic impact, for papers by Alicia‐Marie Conway
Rankless by CCL
2026